← feed

Is NCT02027961 results overdue?

Yes — results are overdue. Primary completion was 2018-04-24; the FDAAA-801 reporting deadline (2019-04-24) passed 2661 days ago and no results are posted on ClinicalTrials.gov.

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT IDNCT02027961 ↗
SponsorMedImmune LLC (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-04-24 (ACTUAL)
Reporting deadline2019-04-24 (completion + 365d)
Days overdue2661
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 6678e2ffefa6ad08… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02027961. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →